Pub. 100-03 Medicare National Coverage Determinations
Upon reconsideration of existing policy, CMS
determines that Autologous Blood-Derived Products for Chronic Non-Healing Cutaneous
Wounds, both platelet-derived growth factor in a platelet-poor plasma, and platelet-rich
plasma (PRP), shall remain noncovered. Coverage for becaplermin, a non-autologous
growth factor for the treatment of chronic non-healing subcutaneous wounds, will remain
at contractor discretion. Exceptions exist to cover the routine costs in Federally
sponsored or approved clinical trials assessing the efficacy of autologous PRP in treating
chronic non-healing cutaneous wounds. (See NCD Manual 310.1.)
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: July 30, 2004
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.